2005 Company Strategic Focus Sharpens
- Three internally developed programs
targeting IND enabling studies
- Enhanced therapeutic area focus on Cancer
and Inflammation
- Strengthened in-house crystallography
capabilities
- Core technology competitiveness demonstrated
via crystallography
- Successful government grant initiatives
- First patent approval on core technology
- Signed third molecular design collaboration
(P&G)
- Acquired Protein Mechanics to solidify
leadership position in computational drug
design
2004 Company and Technology Matures
- Signed first two molecular design collaborations
with DuPont and Speedel
- Obtained confirmatory and pivotal pre-clinical
data
in lead programs
- Initiated crystallography effort to
support major programs
- Implemented comprehensive intellectual
property strategy
- Strengthened management team
- Signed IBM collaboration to allow computing
on demand
2003 Company Infrastructure Evolves
- Three programs are identified and experimental
proof of
concept achieved
- Computational efficiency improved by
400%
- Introduced proprietary computational
tools to improve the
identification of protein binding sites
and small molecule ligands
2002 Company Secures Operational Base
- Senior chemists, biologists, computer
scientists hired
- Moved into headquarters and laboratory
facility in Blue Bell, PA
- Built powerful Linux supercomputer cluster
capable of
2 trillion calculations/second
- Enhanced primary fragment set from 20
to 150
- Initiated internal chemistry and biology
efforts in several programs
- Raised third round of financing: $40MM
2001 Commence Operations
- Senior management hired
- in Zilico experiments validate
technology platform
- Raised second round of financing: $42.75MM
All brand names mentioned enjoy
legal protection. |